Limits...
Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration.

Gaebel R, Furlani D, Sorg H, Polchow B, Frank J, Bieback K, Wang W, Klopsch C, Ong LL, Li W, Ma N, Steinhoff G - PLoS ONE (2011)

Bottom Line: Six weeks post infarction, cardiac catheterization showed significant preservation of left ventricular functions in BM and CD105(+)-CB treated groups compared to CB and nontreated MI group (MI-C).Furthermore, cardiac remodeling can be significantly attenuated by BM-hMSC compared to MI-C.Under hypoxic conditions in vitro, remarkably increased extracellular acidification and apoptosis has been detected from CB-hMSC compared to BM and CD105 purified CB-derived hMSC.

View Article: PubMed Central - PubMed

Affiliation: Reference and Translation Center for Cardiac Stem Cell Therapy (RTC), Department of Cardiac Surgery, University of Rostock, Rostock, Germany.

ABSTRACT
The possible different therapeutic efficacy of human mesenchymal stem cells (hMSC) derived from umbilical cord blood (CB), adipose tissue (AT) or bone marrow (BM) for the treatment of myocardial infarction (MI) remains unexplored. This study was to assess the regenerative potential of hMSC from different origins and to evaluate the role of CD105 in cardiac regeneration. Male SCID mice underwent LAD-ligation and received the respective cell type (400.000/per animal) intramyocardially. Six weeks post infarction, cardiac catheterization showed significant preservation of left ventricular functions in BM and CD105(+)-CB treated groups compared to CB and nontreated MI group (MI-C). Cell survival analyzed by quantitative real time PCR for human GAPDH and capillary density measured by immunostaining showed consistent results. Furthermore, cardiac remodeling can be significantly attenuated by BM-hMSC compared to MI-C. Under hypoxic conditions in vitro, remarkably increased extracellular acidification and apoptosis has been detected from CB-hMSC compared to BM and CD105 purified CB-derived hMSC. Our findings suggests that hMSC originating from different sources showed a different healing performance in cardiac regeneration and CD105(+) hMSC exhibited a favorable survival pattern in infarcted hearts, which translates into a more robust preservation of cardiac function.

Show MeSH

Related in: MedlinePlus

Infarction size 6 weeks after MI.A. Representative ventricular cross sections of heart level c. B. Ratio of infarction size to entire LV is significantly decreased in MI-BM and MI-CB105+ compared to MIC.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3037376&req=5

pone-0015652-g003: Infarction size 6 weeks after MI.A. Representative ventricular cross sections of heart level c. B. Ratio of infarction size to entire LV is significantly decreased in MI-BM and MI-CB105+ compared to MIC.

Mentions: Ligation of the LAD consistently resulted in a transmural MI with its typical histologic changes including the thinning of the left ventricular free wall (Fast green) and extensive collagen deposition (Sirius red) 6 weeks after infarction. Representative heart sections 6 weeks after myocardial infarction following hMSC application or no injection of cells in the MI-C group are shown in Figure 3A. All hMSC treated animals show a markedly smaller infarct size, while the application of human BM- and CD105-purified CB-hMSC could significantly reduce (p<0.05) the myocardial damage compared to MI-C (Figure 3B).


Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration.

Gaebel R, Furlani D, Sorg H, Polchow B, Frank J, Bieback K, Wang W, Klopsch C, Ong LL, Li W, Ma N, Steinhoff G - PLoS ONE (2011)

Infarction size 6 weeks after MI.A. Representative ventricular cross sections of heart level c. B. Ratio of infarction size to entire LV is significantly decreased in MI-BM and MI-CB105+ compared to MIC.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3037376&req=5

pone-0015652-g003: Infarction size 6 weeks after MI.A. Representative ventricular cross sections of heart level c. B. Ratio of infarction size to entire LV is significantly decreased in MI-BM and MI-CB105+ compared to MIC.
Mentions: Ligation of the LAD consistently resulted in a transmural MI with its typical histologic changes including the thinning of the left ventricular free wall (Fast green) and extensive collagen deposition (Sirius red) 6 weeks after infarction. Representative heart sections 6 weeks after myocardial infarction following hMSC application or no injection of cells in the MI-C group are shown in Figure 3A. All hMSC treated animals show a markedly smaller infarct size, while the application of human BM- and CD105-purified CB-hMSC could significantly reduce (p<0.05) the myocardial damage compared to MI-C (Figure 3B).

Bottom Line: Six weeks post infarction, cardiac catheterization showed significant preservation of left ventricular functions in BM and CD105(+)-CB treated groups compared to CB and nontreated MI group (MI-C).Furthermore, cardiac remodeling can be significantly attenuated by BM-hMSC compared to MI-C.Under hypoxic conditions in vitro, remarkably increased extracellular acidification and apoptosis has been detected from CB-hMSC compared to BM and CD105 purified CB-derived hMSC.

View Article: PubMed Central - PubMed

Affiliation: Reference and Translation Center for Cardiac Stem Cell Therapy (RTC), Department of Cardiac Surgery, University of Rostock, Rostock, Germany.

ABSTRACT
The possible different therapeutic efficacy of human mesenchymal stem cells (hMSC) derived from umbilical cord blood (CB), adipose tissue (AT) or bone marrow (BM) for the treatment of myocardial infarction (MI) remains unexplored. This study was to assess the regenerative potential of hMSC from different origins and to evaluate the role of CD105 in cardiac regeneration. Male SCID mice underwent LAD-ligation and received the respective cell type (400.000/per animal) intramyocardially. Six weeks post infarction, cardiac catheterization showed significant preservation of left ventricular functions in BM and CD105(+)-CB treated groups compared to CB and nontreated MI group (MI-C). Cell survival analyzed by quantitative real time PCR for human GAPDH and capillary density measured by immunostaining showed consistent results. Furthermore, cardiac remodeling can be significantly attenuated by BM-hMSC compared to MI-C. Under hypoxic conditions in vitro, remarkably increased extracellular acidification and apoptosis has been detected from CB-hMSC compared to BM and CD105 purified CB-derived hMSC. Our findings suggests that hMSC originating from different sources showed a different healing performance in cardiac regeneration and CD105(+) hMSC exhibited a favorable survival pattern in infarcted hearts, which translates into a more robust preservation of cardiac function.

Show MeSH
Related in: MedlinePlus